Loading
Total declarations
Company
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Latest filing published 10 Aug 2022 for Catalyst Biosciences, INC., €1,496. Read the official filing
Filing timeline
BuySaleGrant E. Blouse
Insider track record
Disclosed buys
3
Disclosed sells
0
Signal history
Closed purchases
Market purchases
3
Positive at T+90
0%
Median T+90
-23.5%
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +67.9%Entry 112.00 · Close at T+365 188.00
- -56.7%Entry 203.00 · Close at T+365 88.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Grant E. Blouse: trading record in brief
Grant E. Blouse (senior executive) discloses dealings in Gyre Therapeutics, Inc. to SEC (Form 4). Between 9 August 2021 and 9 August 2022, the trades on record add up to 3 filings.
Purchases make up the whole of the open-market record (3 purchases, €6,392). Unlike grants, an open-market purchase is paid for by the insider, at the market price. Since January 2022: 2 purchases and no sales on the market.
A typical purchase (the median) is worth €1,496. On 3 out of 3 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.
Most recently, on 10 August 2022, the filings show an open-market purchase worth €1,496 in Gyre Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Grant E. Blouse
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations2 total
3,250 shares@ US$0.4723.4% of flowCommon StockSEC:0001209191-22-045251:0
Canonical exit: 7 Nov 2022 (T+90)
3,250 shares@ US$0.4620.5% of flowCommon StockSEC:0001209191-22-010392:0
Canonical exit: 10 May 2022 (T+90)
1,163 shares@ US$3.6256.1% of flowCommon StockSEC:0001209191-21-050757:0
Canonical exit: 7 Nov 2021 (T+90)
3 of 2 declarations
